Skip to main content

Drug Safety Update

From:
Medicines and Healthcare products Regulatory Agency
Skip to results
  • Letters and drug alerts sent to healthcare professionals in January 2019

    Letters were sent to healthcare professionals about Lartruvo▼ (olaratumab), quadrivalent influenza vaccine (split virion, inactivated), SGLT2 inhibitors, and carbimazole and thiamazole (synonym: methimazole)-containing products.…

    • Therapeutic area: Anaesthesia and intensive care and 8 others
    • Published:
  • Carbimazole: risk of acute pancreatitis

    If acute pancreatitis occurs during treatment with carbimazole, immediately and permanently stop treatment. Re-exposure to carbimazole may result in life-threatening acute pancreatitis with a decreased time to onset.

    • Therapeutic area: Endocrinology, diabetology and metabolism and 1 others
    • Published:
  • Carbimazole: increased risk of congenital malformations; strengthened advice on contraception

    Carbimazole is associated with an increased risk of congenital malformations, especially when administered in the first trimester of pregnancy and at high doses. Women of childbearing potential should use effective contracep…

    • Therapeutic area: Endocrinology, diabetology and metabolism and 3 others
    • Published: